Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?
- 1 March 2004
- journal article
- editorial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (5) , 600-602
- https://doi.org/10.1016/j.amjcard.2003.11.025
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In VivoCirculation, 2002
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002
- Peroxisome Proliferator-Activated Receptor γ Activators Inhibit Cardiac Hypertrophy in Cardiac MyocytesCirculation, 2001
- Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA AvailabilityDiabetes, 2001
- β-Cell Mass Dynamics in Zucker Diabetic Fatty RatsDiabetes, 2001
- Thiazolidinediones (PPARγ agonists) but not PPAR α agonists increase IRS‐2 gene expression in 3T3‐L1 and human adipocytes1The FASEB Journal, 2000
- Peroxisome Proliferator–Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-α Expression in Neonatal Rat Cardiac MyocytesCirculation Research, 2000
- Peroxisome proliferator‐activated receptors in the cardiovascular systemBritish Journal of Pharmacology, 2000
- PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes.Journal of Clinical Investigation, 1998
- Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.Endocrinology, 1995